Clinical Trials Directory

Trials / Completed

CompletedNCT00728715

Efficacy of Budesonide-Formoterol in Bronchiectasis

Clinical Efficacy and Safety of Budesonide and Formoterol in the Management of Non-Cystic Fibrosis Bronchiectasis

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
40 (estimated)
Sponsor
Hospital General de Requena · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Some studies have concluded that high-dose inhaled steroids (IS) are effective in the clinical control of patients with bronchiectasis, however the high doses needed provokes some adverse effects and lower doses are not effective. Combined treatment with budesonide and formoterol have demostrated to be effective in patients with asthma and COPD achieving the reduction of steroid dose thanks to the adition of a long-acting beta 2 agonists. There are no studies in the literature analysing the effect of combined treatment in patients with bronchiectasis. The objective of this study is to compare the efficacy and safety of formoterol-medium dose of budesonide in a single inhaler versus high-dose of budesonide in the clinical control of patientes with non-cystic fibrosis bronchiectasis. Study Design: Randomized (3 months) parallel groups study. Patients: Patients with bronchiectasis diagnosed by high-resolution CT scan and chronic obstructive airway obstruction. Exclusion: Asthma and current or past smokers. Methods: Run in period in all patients with high dose of budesonide (1600 mcg/day) for 3 months. After that, randomization into two groups: 1. The same treatment (1600 mcg/day of budesonide) or combined treatment with lower dose of budesonide (18 mcg/day of formoterol and 800 mcg of budesonide) in a single turbuhaler inhaler during 3 months. Studied variables: Clinical, functional, quality of life, microbiological and number of side effects.

Conditions

Interventions

TypeNameDescription
DRUGbudesonide-formoterol single inhalerHigh dose budesonide:Budesonide (Pulmocort turbuhaler) 400 mcg (2 inhalations bid) Medium dose budesonide plus formoterol (Rilast turbuhaler) 4,5 mcg of formoterol plus 400 mcg of budesonide: 2 inhalations bid
DRUGHigh dose of budesonide1600 mcg/d of budesonide
DRUGAmedium dose of budesonide-formoterol
DRUGBHigh Dose Inhaled Budesonide

Timeline

Start date
2004-01-01
Primary completion
2005-01-01
Completion
2005-01-01
First posted
2008-08-06
Last updated
2008-08-06

Locations

1 site across 1 country: Spain

Source: ClinicalTrials.gov record NCT00728715. Inclusion in this directory is not an endorsement.

Efficacy of Budesonide-Formoterol in Bronchiectasis (NCT00728715) · Clinical Trials Directory